Friday, February 24, 2012

According to the protease antiprotease hypothesis

Nature Medicine 11, 471 - 472 (2005)


DOI: 10. 1038/nm0505-471


authors of Yale University, Department of Medicine, New Haven, Connecticut 06520, USA. Ceramides lipid mediator contributes to tissue destruction in emphysema by promoting apoptosis of structural cells in the lungs. This finding challenges the conventional hypothesis of the pathogenesis of emphysema (


). Chronic bronchitis and emphysema are closely associated with cigarette smoking and outdoor cooking, and pressing unmet medical needs worldwide. In the United States, these diseases affect more than 16 million people, another 50 million at risk under the influence of cigarette smoke. In China, 1. 5000000 people projected to die from these diseases each year over the next 50 years. In contrast, the striking impact on society, we are completely absent in pharmacological agents that alter the natural history of disease and decrease the rate of loss of lung function. This deficiency is due, largely, in our limited knowledge of the pathogenesis of the disease. In this issue Petrakova and colleagues solve this urgent need. They show that ceramides lipid mediator appear apoptosis of cells in the lungs of mice, leading to pulmonary emphysema. The authors further support the relevance of these data to humans, shows that ceramides upregulated in the lungs of patients with bronchitis and emphysema. Chronic bronchitis and emphysema overlapping conditions that often occur simultaneously, and, consequently, will be combined under diagnosis of COPD (chronic obstructive pulmonary disorder). Chronic bronchitis is diagnosed in patients with inexplicable cough and sputum production that lasts for more than two years and can not be associated with any other disorder. Light from the people with the disease have increased the number and size of mucus glands, a condition called mucous metaplasia. Emphysema is defined pathologically based on the destruction of alveolar walls, the site in the lungs, where absorption of oxygen and removing carbon dioxide occurs. Localized fibrosis and collagen and violation occurs, and many leukocyte populations contribute to inflammation and tissue infiltration in COPD tissues. In 1960, protease antiprotease hypothesis was the dominant concept in the pathogenesis of emphysema. This theory assumes that the 'shield' antiprotease protects normal day in day light effects that can increase the response easy proteolytic. It also suggests that emphysema occurs when inflammation or antioxidants cause an increase or decrease of proteases in antiproteases. Due to the popularity of CD8


regulated genes of T cells 1T helper type 1 (T. According to the theory, protease excess may damage the matrix, which generates a small "holes", areas of local attenuation, or both. With repeated trauma, holes merge, leading to rupture of alveolar walls. important to note that endothelial cell damage and alveolar epithelial cells of the primary events that traditionally are not part of this concept. Although protease antiprotease hypothesis was useful for design studies of the pathogenesis of emphysema is now clear it explains only some aspects of this disease. recent alternative hypothesis was entertained. This hypothesis suggests that damage cells, causing apoptosis of structural cells in the lungs is a major event in the pathogenesis of emphysema .. Later studies showed that apoptosis depends on emphysema lung induced blockade of vascular endothelial growth factor cells (VEGF) and activated caspase vnutrilehochnoho Administration 3 (link


). This work also showed that, unlike the standard conceptualization, apoptosis of structural cells in the lungs is not soft events . Instead, apoptosis contributes to the accumulation of local protease that can feed to the degradation of proteins in the matrix are the alveolar walls. It is clear from these studies that the alveoli depends on the integrity of endothelial and epithelial cells with loss or lead to structural changes and possibly emphysema. different molecular mediators involved in the pathogenesis of emphysema. According to the protease antiprotease hypothesis and the power of modern molecular biology, these studies were directed almost exclusively on proteins that function as proteases and antiproteases. These studies showed that the number of proteases, including neutrophil protein granules, matrix metalloproteinazy


and cathepsin involved in the degradation of collagen, elastin and other proteins of the matrix that occurs in emphysema. unique cathepsin-mediated apoptosis of epithelial and the way it was shown that the contribution leads to emphysema caused by T. In all cases, these responses are modulated proteolytic batteries including antiproteases


-1 antitrypsin deficiencyinduced emphysema. Ceramide is strictly regulated sfinholipidiv second conciliator. molecules made by different tissues in response to several stimuli, including endotoxins, oxidative stress and cytokines. Ceramide coordinates responses to stress modulates oxidative and proliferative responses and is a potent inducer of apoptosis. According to this property Petrakova


al. investigated the importance of ceramides in the pathogenesis of emphysema. Their research shows that it ceramides critical mediator of alveolar destruction. To show this, the authors inhibits the enzymes control


re-synthesis of ceramides and noted that the interference prevented apoptosis of alveolar cells, oxidative stress and emphysema in the mouse VEGF-blockade emphysema model. authors also found that ceramides induced emphysema when buried in the lungs of mice, and that stimulation sfynhozyna-1 phosphate, a downstream product of the metabolism of ceramides, which inhibit ceramides to prevent lung apoptosis. next step was to go beyond the mouse and watch the people. These studies have shown that lung ceramides were increased and qualitatively altered in lung tissue from individuals people with smoking-induced emphysema lasix 15 mg. These exciting research for several reasons. They primarily involve non-protein mediator of apoptosis in the pathogenesis of emphysema. In addition, in determining ways of biosynthesis of ceramides and pathways that regulate its effector properties (


), they determine the number of sites where measures may be aimed at trying to control pulmonary emphysema. Finally, given that the ceramides is also in the pathogenesis of atherosclerosis, these studies support the concept that abnormalities ceramides generalized response to the effects of cigarette smoke, and that similar mechanisms of pathogenic contribute to the pathogenesis of COPD, atherosclerosis and other cigarettes, smoking related diseases. complete understanding of the deposits ceramides in emphysema will require further investigation between ceramides changes, tissue proteolysis and inflammation. In particular, a better understanding of the relationship between T


1, inflammation and cathepsin-mediated apoptosis is important. It is however clear that from now on, apoptosis and lipid mediators must be taken into account when trying to understand the pathways leading to alveolar destruction and emphysema. Petrakova, I., et al . Nat. Med. 11, 491498 (2005) |.


Hogg, JC et al N. Engl J. Med 350, 26452653 (2004) | ....


| | | .. Saetta , M. et al Is J. Respir. Critical Care Med 160, 711717 (1999) | ...


| ... Wang, Z. et al, J. Exp Med 192, 15871600 (2000) | .


| | | Grumelli, S.. et al PLoS Med 1 E8 (2004) | ....


Majo J.


Ghezzo, H.anabolic muscle protein Kosoy, M. J. Respir Eur 17, 946953 (2001) |.


| | Segura-Valdez, L. et al Chest 117, 684694 (2000) | ..


| | | ... Kasahara, Y. et al J. Clin Invest 106, 13111319 (2000). |


| | .... Aoshiba K.


Yokohori, N. Nagai, A. Am J. Respir Mobile Molecular Biology 28, 555562 (2003 ) |.


| | GA Finlay ... et al, J. Am Respir Critical Care Med 156, 240247 (1997) | ...


| | Hautamaki, RD,


Kobayashi, DK,


Senior, R. Shapiro, SD Science 277, 20022004 (1997) |.


| | | Ohnishi K


Takagi, M., Kurokawa


, Y.,


Satomi, S. Konttinen, YT Lab Invest 78, 10771087 (1998) | ...


| | .... Zheng, T. et al, J. Immunol (in press ), Kolesnik, RJ Wedge Invest 110, 38 (2002) .. |


| | |

To alleviate these potential side effects, take ...

Osteoporosis Treatment may include medications along with lifestyle changes. Mayo Clinic specialist answers to some frequently asked questions about the treatment of osteoporosis. If you are undergoing treatment of osteoporosis, you do step in the right direction for healthy bones. But you may have many questions about your treatment. There are medications you are taking the best for you? How long you should take it? Why your doctor recommends taking a pill weeks, when your friend takes pills once a month? Kurt nurseries, MD, a specialist in endocrinology at the Mayo Clinic in Rochester, Minn., answers to frequently asked questions about the treatment of osteoporosis in women and describes how osteoporosis drugs work. What drugs are widely used to treat osteoporosis? Bisphosphonates most common drugs proposed for treatment of osteoporosis. These include:


ryzedronat (Actonel, Atelvia)


zoledronovoyi acid (Reclast, Zometa)


hormones such as estrogen, and some hormones as drugs approved for the prevention and treatment of osteoporosis, such as raloksifen (Evista), and also play an important role in the treatment of osteoporosis. However, fewer women using estrogen therapy, as this may increase the risk of heart attacks and certain cancers. How do bisphosphonates lasix 260 mg work? Bisphosphonates slow the process of bone breakdown. Healthy bones are in a state of destruction and renewal. As you get older, especially after menopause when your estrogen level decreases, the process accelerates the destruction of bone. When restoring the bones behind, the bones deteriorate and become weaker. Bisphosphonates generally slow in this regard. These drugs effectively preserve and maintain bone density during menopause and reduce the risk of fracture due to osteoporosis. As you know, if you take the right treatment? Preparation class bisphosphonates more in common than they differ. Some studies show differences in potency or efficacy in maintaining bone density, but they are still effective drugs. All bisphosphonates have been shown to reduce the likelihood of fractures. The decision on acceptance of one drug to another, often based on:


Your doctor may recommend a monthly dose if it is better tolerated and more widely accepted. But if you and someone who may forget to take medication every month, you would do better to take once a week. What are the most common side effects of bisphosphonates pills? To alleviate these potential side effects, take medication on an empty stomach with a tall glass of water. Do not lie or bend from 30 to 60 minutes to avoid medicine washing back into the esophagus. Most women who follow this advice, do not experience these side effects. But it may not be lucky few who take medicines properly has indigestion or heartburn. .

Boniva may cause serious side effects, including ...

BONIVA is buy lasix generic online a prescription medication used to treat and prevent osteoporosis in women after menopause. BONIVA helps to increase bone mass and reduces the likelihood of fracture of the spine (break). It is not known how long is BONIVA for treatment and prevention of osteoporosis. You should regularly visit the doctor to determine, BONIVA is still for you. You should not take BONIVA, if you have some problems with the esophagus (tube that connects mouth and stomach), low blood calcium, can not sit or stand for at least 60 minutes, or are allergic to BONIVA or any of its components. BONIVA may cause serious side effects, including problems with your esophagus, low calcium in the blood, bones, joints and muscle pain, severe problems with the jaw bone, and unusual fractures of the hip. Before BONIVA tell your doctor if you have trouble swallowing, stomach or digestive problems, have low blood calcium, plan the dentist or teeth removed or kidney problems. Stop taking BONIVA and tell your doctor if you have pain or trouble swallowing, chest pain or heavy or continuing heartburn, as it can be a sign of serious upper digestive problems. Call your doctor if the problem with the jaw, hip, groin or thigh pain develop, or if you have symptoms of low blood calcium, such as seizures, twitching, muscle cramps, or numbness or tingling in fingers and toes or around the mouth. Follow the directions for dosing once monthly BONIVA carefully. The most common side effects: back pain, heartburn, pain in the abdomen, pain in hands and feet, diarrhea, headache, muscle aches, and flu-like symptoms. You are encouraged to report negative side effects of drugs to the FDA or call 1-800-FDA-1088. Talk to your doctor for more information or if you have questions about your treatment. Complete and additional information on safety. .

Block {background: none; float: none;}

SharethisIco. shareCounter {


background: URL ("/ Design/Images/shareleft_15 picture.") does not repeat scroll 100% 0 # 69C023;


color: # FFFFFF! important;


display: block;


float: left;


height: 15px;


padding: 0 6px 0 3px;


alignment: center;


}. shareiconToolbar. atlData. t30 {top: 20px! important;}. shareiconToolbar buy lasix 100 mg. scrlBlock {background: none; float: none;}


/ *. shareiconToolbar. posRel. shareiconToolbar. btnCls {background: none;} * /


/ *. shareiconToolbar cases. posRel {width: 200px; float: left;}. shareiconToolbar cases. btnCls {width: 10px; float: left;} * /. shareLink interval {


color: # FFFFFF! important;


height: 15px;


alignment: center;}


. sharethisIco. shareLink {


background: URL ("/ Design/Images/share_15 picture.") does not repeat scroll 0 0 # 69C023;


display: block;


float: left;


padding: 0 5px 0 15px;}


. gplusIco {


background: URL ("/ Design/Images/gPlusicon15 JPG.") no-repeat scroll 0 0 transparent;


width: 24px ! important;


}. shareiconToolbar {


cursor: pointer;


display: built-in unit;


min width: 15px;


text-decoration: none;


width: auto! important;


}. shareiconToolbar {


bottom border: 1px solid # 707173;


display: built-in unit;


float: left;


Font size: 10px;


height: 15px; << row >> height: 15px;


margin: 0;


padding: 0 0 5px;


width: 100%;}


shareIco {


. float: left;


margin: 0 0 0 6px;


min width: 15px;


padding: 0;


alignment: center;


width: auto! important;


}. sharethisIco {


float: left;


min width: 45px;


width: auto! important;


}. facebookIco {


background: URL (". / design / Images / facebookIco PNG") not to repeat scroll 0 0 transparent;}


. twitterIco {


background: URL (". / design / Images / twitterIco PNG") not to repeat scroll 0 0 transparent;}


. linkedinIco {


background: URL (". / design / Images / linkedinIco PNG") not to repeat scroll 0 0 transparent;}


. gplusIco {



background: URL ("/ Design/Images/gPlusicon15 JPG.") no-repeat scroll 0 0 transparent;


width: 24px! important;


}. facebookIco. twitterIco. linkedinIco. gplusIco {


cursor: pointer;


display: block;


float: left;


height: 15px;


overflow: hidden;


text paragraph: - 9999px;


}. shareiconToolbar. textLink {


display: built-in unit;


float: left;


margin: 0 0 0 6px;


padding: 0;


width: auto;


}. textLink {


background: URL (". / design / Images / liSeperatorJournals picture") does not repeat scroll left 1px transparent;


color: # 707173;


display: block;


float: left;


margin: 0 0 0 6px! important;


padding: 0 0 0 7 pixels;


text alignment: left;


text-decoration: none;


width: auto;}


. shareLink {


background: URL ("/ Design/Images/share_15 picture.") does not repeat scroll 0 0 # 69C023;


display: block;


float: left;


padding: 0 5px 0 15px;}


shareiconToolbar. CLHolder. atlData. btnCls. atlData. btnCls {border: 0 none; display: block height: 8px; margin: 0; padding: 2px 2px 4px 6px; alignment: right, text-decoration: none; width: 110px; status: relative! important, float: left}. shareiconToolbar. CLHolder. atlData. btnCls. atlData. btnCls {position: absolute; right: 0; bottom: 0; background image: No! important}. shareiconToolbar. CLHolder. atlData. btnCls IMG. atlData. btnCls IMG {border: 0 none; height: 9px, width: 9 points, float: right! important;}. shareiconToolbar. first {background-image: No! important, filling the left: 0px! important}. shareiconToolbar. CLHolder. atlData. atlData cases. posRel span {background-image: No! important}. shareiconToolbar. textLink: when you hover {color: # 1b79b3! important text-decoration: none;}. atlData. scrlBlock: when you hover. atlData. scrlBlock. act {background color: # d9dadb! important color: # 3e3d40! important}. atlData {color: # 3e3d40! important}.


.

Copd.

Your browser does not support inline frames or is not configured to display inline frames. The first commercial use InterVapor absorption Medications


system for endoscopic lung volume reduction in patients with severe emphysema >> << have been made in Germany last November. The patient was successfully treated with InterVapor, >> << endoscopic lung volume reduction system for the treatment of severe emphysema >> << that uses bodyBЂ ™ natural healing process, leaving no foreign material


in the lungs. The patient was treated


Team Thoraxklinik in Heidelberg, Germany, led by


Prof. Dr. Felix Herth and is recognized as a leading institution


on the latest therapeutic options for people with emphysema. BЂњAs investigators in court a couple, we saw the benefits most common side effects of lasix


our patients received InterVapor, and we are pleased to enter


Selected InterVapor, BЂ "commented Prof. Dr. Felix


Herth, Chief, Department of Pulmonology, Thoraxklinik


Heidelberg. BЂњIt especially fitting that the first patient case


in November, which marks the COPD Awareness Month, as


InterVapor offers a new treatment option for patients who


looking for help from emphysema. BЂ "


Medical Acquisitions announced on 9 January this year, it closed


series C funding cycle. Round-headed Singapore


Group Point Crescent, existing investors, Maverick Capital,


Ventures beginning, GBS Venture Partners, WRF Capital, arboretum


Ventures and Affinity Capital, making additional investments. Sami


Cindy, crescent point, Managing Partner, will enter the acquisition of medical


Board of Directors. Moelis Company acted as financial advisor


Company in connection with the financing. The company has received CE mark approval to InterVapor in September


and recently announced the TGA approval InterVapor on the market


Australia. R. King Nelson, President and CEO of Acquisitions


Medical commented BЂњFinalizing a very successful round of financing


is another positive step for the absorption of Medical. We


pleased with the addition of Crescent Point to our board and we


equally pleased that our current investors are still committed


absorption of medical, as we continue to commercialize InterVapor. BЂ "


About emphysema / COPD Emphysema is a progressive disease in which lung


damaged. This leads to a condition called


hyperinflation, which affects the respiratory function and makes patients


make short, shallow breaths, greatly affects quality of life. InterVapor system directly causes the reduction of hyperinflation


problem for patients with severe emphysema. This non-surgical


procedure that applies to the hyperinflated lung units with heating


water vapor, and starts a natural healing process bodyBЂ ™ s,


gradually reducing considered part of the lungs and increase the ability to breathe


more fully. Unlike other approaches to reduce lung volume, InterVapor does not leave


foreign matter in the lungs, which may require additional procedures


to set up or removal. The results obtained in court


PAIR demonstrated clinically significant improvement in lung function


and quality of life for patients with severe emphysema. Global incidence of chronic obstructive pulmonary disease


(COPD), which includes emphysema, is on the rise, and will >> << third leading cause of death in 2030. In the U.S., where nearly 5


million people are diagnosed with emphysema, she already holds this position


with one person dying every 4 minutes from COPD. Exhausting and expensive, almost $ 50 billion was spent solution >> << direct and indirect costs of COPD in the U.S. in 2010. .


Celebrities observer in london - october ...

Whitney Houston arrived at Fountain Studios October 18, 2009 in London, England. Observations celebrity in London - October 18, 2009 London, England UK 18 October 2009 Photo: Sam Snap / FilmMagic. com to license the image (58676261), contact FilmMagic. com


Sam Snap / FilmMagic. com


Whitney Houston arrived at Fountain Studios October 18, 2009 in London, England.anabolic steriod Observations celebrity in London - October 18, 2009 London, England UK 18 October 2009 Photo: Sam Snap / FilmMagic. com to license the the drug lasix image (58676263), contact FilmMagic. com


Sam Snap / FilmMagic. com


singer Whitney Houston's speech to the German game show "Wetten Dasso ...?" (Betting it ...?) in Freiburg, southwest Germany, Saturday, October 3, 2009. "Wetten Dasso ...?" Is one of the most popular programs on Saturday night in Germany. (AP Photo / Johannes Ayzele, pool)


U.S. singer Whitney Houston talks with TV presenter Thomas Gottschalk in the 183-th edition of the TV show presented by "Wetten, Dasso? .. "(Let's make rate) October 3, 2009 in Freiburg, southern Germany. AFP PHOTO DDP / JOERG KOCH GERMANY OUT (Photo must read JOERG KOCH / AFP / Getty Images)


U.S. singer Whitney Houston appears on stage during one hundred and eighty third issue of TV show presented by «Wetten, Dasso? .. "(Let's make a bet) on October 3, 2009 in Freiburg, southern Germany. AFP PHOTO DDP / JOERG KOCH GERMANY OUT (Photo must read JOERG KOCH / AFP / Getty Images)


U.S. singer Whitney Houston appears on stage during one hundred and eighty third issue of TV show presented by «Wetten, Dasso? .. "(Let's make a bet) on October 3, 2009 in Freiburg, southern Germany. AFP PHOTO DDP / JOERG KOCH GERMANY OUT (Photo must read JOERG KOCH / AFP / Getty Images)


U.S. singer Whitney Houston appears on stage during one hundred and eighty third issue of TV show presented by «Wetten, Dasso? .. "(Let's make a bet) on October 3, 2009 in Freiburg, southern Germany. AFP PHOTO DDP / JOERG KOCH GERMANY OUT (Photo must read JOERG KOCH / AFP / Getty Images)


U.S. singer Whitney Houston appears on stage during one hundred and eighty third issue of TV show presented by «Wetten, Dasso? .. "(Let's make a bet) on October 3, 2009 in Freiburg, southern Germany. AFP PHOTO DDP / JOERG KOCH GERMANY OUT (Photo must read JOERG KOCH / AFP / Getty Images)


Freiburg in Breyshau, Germany - OCTOBER 03: Singer Whitney Houston's speech Wetten Dasso ...? show at Messe Freiburg October 3, 2009 in Freiburg, Germany. (Photo by Miguel Villagran / Getty Images) *** Local Caption *** Whitney Houston


Freiburg in Breyshau, Germany - OCTOBER 03: Singer Whitney Houston's speech Wetten Dasso ...? show at Messe Freiburg October 3, 2009 in Freiburg, Germany. (Photo by Miguel Villagran / Getty Images) *** Local Caption *** Whitney Houston.

Emphysema usually develops as a result ...

Emphysema (in Greek) means "inflation." In this case, it refers to


Inflation light. Who is at high risk of getting emphysema? Men 50 to 70 years, especially lasix generic those who are heavy smokers are more likely to suffer from that any other age / sex group. As more women start smoking early, more and more women being diagnosed with emphysema. Another group that has a high incident Emphysema includes those who are exposed to air pollutants in the workplace or in (or close to) their homes. Those born with the lack of alpha-1 antitrypsin and more susceptible to emphysema. What are the symptoms of emphysema? Emphysema develops over time. Early symptoms include chronic cough, and chronic bronchitis. The patient often experiences difficulty in breathing, asthma, similar to the symptoms. What is the cause of emphysema? Emphysema usually develops as a result of chronic infection in the airways. Airways (bronchial tubes) get interference, irritated or infected, resulting in violation of oxygenation of blood. If infection persisit for a long time, eventually all light can be increased, reaulting in a condition known as "pneumonia" or emphysema. Again, smoking, effects of air pollutants, and lack of alpha-1 antitrypsin is a leading cause of emphysema. What are the treatment options for emphysema? Stopping smoking is the first step. Bronchial enlargement drugs, medicines for asthma, antibiotics to fight any infections and oxygen therapy, often prescribed. For those who are diagnosed with alpha-1 antitrypsin deficiency alpha-1 antitrypsin infusion on a regular basis as prescribed. Do not forget to check out the section on this site for last and our last Note: Refer to a qualified physician if you suspect lung disease. Information published at this mesothelioma lung disease asbestos cancer forum - or most other websites on the subject - should not be relied upon for health decisions. The information provided on this website is not intended as a substitute for medical care, medical, legal or professional advice. Please talk to your doctor for all your health problems. .